Status:
RECRUITING
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
Lead Sponsor:
Eli Lilly and Company
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
Eligibility Criteria
Inclusion
- Have type 2 diabetes
- Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening
- Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive
- Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)
Exclusion
- Have type 1 diabetes
Key Trial Info
Start Date :
October 13 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07215312
Start Date
October 13 2025
End Date
December 1 2026
Last Update
December 18 2025
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Tucson Clinical Research Institute
Tucson, Arizona, United States, 85712
2
Encompass Clinical Research
Spring Valley, California, United States, 91978
3
University Clinical Investigators, Inc.
Tustin, California, United States, 92780
4
Tampa Bay Medical Research
Clearwater, Florida, United States, 33761